Hypertension Treatment in Nigeria: Hypertension Diabetes Integration Study- Formative Aim 3

Study acronym: HTN2
StatusRecruiting
PhaseNot applicable
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 2 changed
See other at-risk trials from Washington University School of Medicine

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 5 more changesShow less
    • Recruitment opened
    • Trial sites expanded: 0 → 10 locations
    • Start date changed from estimate of May 1, 2026 to Feb 14, 2026
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints: details revised at 9 of 10 entries
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
The purpose of the second phase of the Hypertension Treatment in Nigeria (HTN 2.0) Program is to build upon the success of the first phase of the HTN Program (2020-2023), which implemented the WHO HEARTS package across 60 primary healthcare centers (PHCs) in the Federal Capital Territory (FCT). This program demonstrated significant improvements in hypertension treatment and control. The focus of aim 3 will be evaluating diabetes management through the implementation of the HEARTS-D bundle in 10 PHCs across the FCT that previously participated in the initial HTN Program.
Trial Details
NCT Number NCT07589387
Lead Sponsor Washington University School of Medicine
Collaborators: National Heart, Lung, and Blood Institute (NHLBI), University of Abuja Teaching Hospital
Conditions
(from sponsor)		 Diabete Mellitus
Related terms Diabetes Mellitus
Enrollment 2,800 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov